A global randomized, chemotherapy-doublet controlled phase III trial of savolitinib combination with Tagrisso for the treatment of non-small cell lung cancer (T790M-/c-Met+) patients.
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2016
At a glance
- Drugs Osimertinib (Primary) ; Savolitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Chi-Med
- 02 Aug 2016 According to Chi-Med media release, company targets to initiate this pivotal registration study before the end of H1 2017.
- 22 Jun 2016 New trial record
- 20 Jun 2016 According to a Chi-Med media release, the company plans to initiate this trial in 2017.